Covered recipient · General Payments record
CHARLES FRANKLIN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2023
$1,294.93
- Reported across 69 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $346.64 | 19 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $142.76 | 9 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $101.44 | 4 |
| ABBVIE INC. | $81.48 | 5 |
| Acerta Pharma LLC | $20.96 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.56 | 01/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997288129 | CMS |
| ABBVIE INC. | $17.60 | 01/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997288133 | CMS |
| ABBVIE INC. | $14.89 | 02/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997288137 | CMS |
| ABBVIE INC. | $17.49 | 03/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997288141 | CMS |
| ABBVIE INC. | $16.94 | 03/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997288145 | CMS |
| Amgen Inc. | $19.93 | 01/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857823 | CMS |
| Amgen Inc. | $5.91 | 02/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857801 | CMS |
| Amgen Inc. | $20.46 | 03/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857805 | CMS |
| Amgen Inc. | $6.27 | 04/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857807 | CMS |
| Amgen Inc. | $18.25 | 04/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857811 | CMS |
| Amgen Inc. | $20.85 | 04/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857797 | CMS |
| Amgen Inc. | $26.85 | 05/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857793 | CMS |
| Amgen Inc. | $19.30 | 05/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857815 | CMS |
| Amgen Inc. | $4.94 | 05/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019857819 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.96 | 05/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1014434781 | CMS |
| Novartis Pharmaceuticals Corporation | $31.95 | 02/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991466747 | CMS |
| Novartis Pharmaceuticals Corporation | $27.18 | 03/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991466727 | CMS |
| Novartis Pharmaceuticals Corporation | $23.76 | 03/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991466761 | CMS |
| Novartis Pharmaceuticals Corporation | $18.55 | 03/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991466805 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.